Youdao Provides Update on PRC Regulatory Policy

PR Newswire

HANGZHOU, China, July 26, 2021 /PRNewswire/ — Youdao, Inc. (“Youdao” or the “Company”) (NYSE: DAO), a leading intelligent learning company in China, noted that the General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued a set of guidelines on July 24, 2021, aiming to ease the burden of excessive homework and after-school tutoring for students receiving compulsory education (the “Guidelines”). The Guidelines, among other things, require that all institutions offering online after-school tutoring on academic subjects in compulsory education be registered as non-profit organizations, obtain approval from the relevant regulatory authorities, and comply with various operational requirements with respect to class hours, faculty qualifications, tuition standards, advertising and others. In addition, the Guidelines prohibit all such tutoring businesses from raising funds through stock exchange listings or other capital-related activities. Foreign investments in school curriculum-based tutoring institutions through variable interest entity (VIE) arrangements, mergers and acquisitions or otherwise are also prohibited. Listed companies are banned from raising capital through equity offerings to invest in businesses offering tutoring on academic subjects in compulsory education. The Guidelines require that all businesses that have already violated these rules take corrective measures as appropriate.  

Although the interpretation and implementation of the Guidelines remain uncertain, we expect the Guidelines to have material impacts on our K-12 course business, financial condition and corporate structure. As we are currently exploring measures to comply with the requirements in the Guidelines for our K-12 course business, we will continue to seek guidance from regulatory authorities to improve our operations in strict compliance with all laws and regulations, fulfil our social responsibilities, provide our users with high-quality, innovative products and services, and promote the long-term development of China’s education industry.

About Youdao, Inc.

Youdao, Inc. (NYSE: DAO) is a leading intelligent learning company in China dedicated to developing and using technologies to provide learning content, applications and solutions to users of all ages. Building on the popularity of its online knowledge tools such as Youdao Dictionary and Youdao Translation, Youdao now offers online courses covering a wide spectrum of age groups, subject matters, learning goals and areas of interest. In addition, Youdao has developed a variety of interactive learning apps and smart learning devices. Youdao was founded in 2006 as part of NetEase, Inc. (NASDAQ: NTES; HKEX: 9999), a leading internet technology company in China. For more information, please visit: http://ir.youdao.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding such risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact: 

In China:

Jeffrey Wang

Youdao, Inc.
Tel: +86-10-8255-8163 ext. 89980
E-mail: [email protected]

The Piacente Group, Inc.
Emilie Wu
Tel: +86-21-6039-8363
E-mail: [email protected]

In the United States:

The Piacente Group, Inc. 
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/youdao-provides-update-on-prc-regulatory-policy-301340861.html

SOURCE Youdao, Inc.

SPX FLOW Announces Exploration Of Strategic Alternatives

PR Newswire

CHARLOTTE, N.C., July 26, 2021 /PRNewswire/ — SPX FLOW, Inc. (NYSE: FLOW), a leading provider of process solutions, today announced that its Board of Directors has authorized a review of strategic alternatives, including a possible sale or merger of the Company and the continued execution of the Company’s standalone strategy. Previously, the Company announced that its Board of Directors had received and rejected an unsolicited, conditional, non-binding proposal from Ingersoll Rand Inc. (NYSE: IR) to acquire all outstanding shares of SPX FLOW common stock for $85.00 per share. This followed a similar unsolicited proposal from Ingersoll Rand for $81.50 per share.

After careful review with its legal and financial advisors, and with the recommendation of a committee of independent directors formed to evaluate the potential transaction, the Board concluded that the proposals did not adequately value the Company in light of the Board’s confidence in the potential for increased profit margins and growth associated with the Company’s successful execution of its strategic plan.

As a result of additional inquiries received from interested parties, the Board believes it is appropriate to initiate its review of a broad range of strategic alternatives with the goal of delivering the most value to our shareholders. With the assistance of outside advisors, the Company expects to engage with multiple parties and, subject to customary confidentiality and other protections, share additional information relating to the Company and its growth plans.

No assurances can be given regarding the outcome or timing of the review process. SPX FLOW does not intend to make any further public comment regarding the review until it has been completed or the Company determines that disclosure is required or appropriate.

Morgan Stanley & Co. LLC is serving as SPX FLOW’s financial advisor and Winston & Strawn LLP is acting as its legal advisor.

About SPX FLOW, Inc.

Based in Charlotte, N.C., SPX FLOW, Inc. (NYSE: FLOW) improves the world through innovative and sustainable solutions. The company’s product offering is concentrated in process technologies that perform mixing, blending, fluid handling, separation, thermal heat transfer and other activities that are integral to processes performed across a wide variety of markets for nutrition, health and precision solutions. SPX FLOW had approximately $1.4 billion in 2020 annual revenues and has operations in more than 30 countries and sales in more than 140 countries. To learn more about SPX FLOW, please visit www.spxflow.com.

Certain statements contained in this announcement that are not historical facts, including any statements as to future market conditions, results of operations and financial projections, are forward-looking statements and are thus prospective. These forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from future expressed or implied results.

Although SPX FLOW believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Estimates of future operating results are based on the company’s continuing operations, which are subject to change.

Particular risks facing SPX FLOW include risks relating to economic, business and other risks stemming from changes in the economy, the impact of the COVID-19 pandemic, our international operations, legal and regulatory risks, cost of raw materials, and pricing pressures.  More information regarding such risks can be found in SPX FLOW’s SEC filings.

Statements in this presentation are only as of the time made, and SPX FLOW does not intend to update any statements made in this presentation except as required by regulatory authorities.

Investor Contact:

Scott Gaffner

VP, Investor Relations and Strategic Insights
704-752-4485
[email protected]

Media Contact:

Melissa Buscher

Chief Communications and Marketing Officer
704-449-9187
[email protected]  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/spx-flow-announces-exploration-of-strategic-alternatives-301340773.html

SOURCE SPX FLOW, Inc.

Volta Charging Announces New Station Installation In Renton, Washington

PR Newswire

SAN FRANCISCO, July 26, 2021 /PRNewswire/ — Volta Industries, Inc. (“Volta Charging”), an industry leader in commerce-centric electric vehicle (EV) charging networks, which has entered into a definitive agreement for a business combination with Tortoise Acquisition Corp. II (NYSE: SNPR), announced today that it has further extended its market penetration with the installation of new charging stations at Safeway in Renton, Washington. The exact address of these charging stations is 2725 NE Sunset Boulevard, Renton, Washington 98056.

Founded on the premise that the electrification of mobility is likely to be one of the largest infrastructural shifts of this generation, Volta Charging builds and operates a nationwide EV charging network that is among the best utilization per station for the United States. Centered around capturing new spending habits expected to result from the shift to electric vehicles, Volta Charging seeks to transform the fueling industry by building open-network charging stations in locations where drivers already spend their time and money, including grocery stores, pharmacies and other retail locations.

The charging stations at Safeway furthers Volta Charging’s mission to build convenient, simple and delightful charging infrastructure that is seamlessly incorporated into a driver’s everyday experience. There are now 24 Safeway locations in Washington with Volta Charging stations.   

About Volta Charging

Volta Charging is an industry leader in commerce-centric EV charging networks. Volta Charging’s vision is to build EV charging networks that capitalize on and catalyze the shift from combustion-powered miles to electric miles by placing stations where consumers live, work, shop and play. By leveraging a data-driven understanding of driver behavior to deliver EV charging solutions that fit seamlessly into drivers’ daily routines, Volta Charging’s goal is to benefit consumers, brands and real-estate locations while helping to build the infrastructure of the future.  As part of Volta Charging’s unique EV charging offering, its stations allow it to enhance its site hosts’ and strategic partners’ core commercial interests, creating a new means for them to benefit from the transformative shift to electric mobility. To learn more, visit www.voltacharging.com.

In February 2021, Volta Charging and Tortoise Acquisition Corp. II (NYSE: SNPR), a publicly traded special purpose acquisition company with a strategic focus on energy sustainability and decarbonizing transportation, announced they entered into a business combination agreement. Upon the closing of the transaction, which remains subject to customary closing conditions, the combined entity will be named Volta Inc. and remain on the New York Stock Exchange under the new ticker symbol “VLTA”.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/volta-charging-announces-new-station-installation-in-renton-washington-301340675.html

SOURCE Volta

KBR Secures Contract for Lithium Concentration Process from Neo Lithium Corp.

PR Newswire

HOUSTON, July 26, 2021 /PRNewswire/ — KBR (NYSE: KBR) announced today it has been awarded a contract by Neo Lithium Corp. in Argentina for its Tres Quebradas Lithium Project (“3Q Project”). Under the terms of the contract, KBR will implement its evaporation and crystallization technology solutions to ensure the project achieves maximum lithium yields for Neo Lithium’s battery-grade lithium carbonate production.

“We are proud to be selected by Neo Lithium for this breakthrough project focused on producing high- quality battery-grade lithium carbonate,” said Doug Kelly, KBR President, Technology. “This award reinforces our commitment to help our clients achieve their growth objectives in the most sustainable manner.”

KBR’s process knowledge for recovery and purification of inorganic materials is based on over 40 years of experience in designing evaporation and crystallization technologies that comply with today’s demanding environmental regulations.

About KBR

We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 29,000 people worldwide with customers in more than 80 countries and operations in 40 countries.

KBR is proud to work with its customers across the globe to provide technology, value-added services, and long- term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.

Visit www.kbr.com  

Forward Looking Statement

The statements in this press release that are not historical statements, including statements regarding future financial performance, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond the company’s control that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the significant adverse impacts on economic and market conditions of the COVID-19 pandemic; the company’s ability to respond to the challenges and business disruption presented by the COVID-19 pandemic; the recent dislocation of the global energy market; the company’s ability to realize cost savings and efficiencies relating to the streamlining of its Energy Solutions business; the company’s ability to manage its liquidity; the company’s ability to continue to generate anticipated levels of revenue, profits and cash flow from operations during the COVID-19 pandemic and any resulting economic downturn; the outcome of and the publicity surrounding audits and investigations by domestic and foreign government agencies and legislative bodies; potential adverse proceedings by such agencies and potential adverse results and consequences from such proceedings; the scope and enforceability of the company’s indemnities from its former parent; changes in capital spending by the company’s customers, including as a result of the COVID-19 pandemic; the company’s ability to obtain contracts from existing and new customers and perform under those contracts; structural changes in the industries in which the company operates; escalating costs associated with and the performance of fixed-fee projects and the company’s ability to control its cost under its contracts; claims negotiations and contract disputes with the company’s customers; changes in the demand for or price of oil and/or natural gas; protection of intellectual property rights; compliance with environmental laws; changes in government regulations and regulatory requirements; compliance with laws related to income taxes; unsettled political conditions, war and the effects of terrorism; foreign operations and foreign exchange rates and controls; the development and installation of financial systems; increased competition for employees; the ability to successfully complete and integrate acquisitions; and operations of joint ventures, including joint ventures that are not controlled by the company.

KBR’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks, and other U.S. Securities and Exchange Commission filings discuss some of the important risk factors that KBR has identified that may affect the business, results of operations and financial condition. Except as required by law, KBR undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kbr-secures-contract-for-lithium-concentration-process-from-neo-lithium-corp-301340686.html

SOURCE KBR, Inc.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

PR Newswire

NEW YORK, July 26, 2021 /PRNewswire/ –BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.

BrainStorm Cell Therapeutics Logo

BrainStorm’s Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, Stacy Lindborg, PhD, Executive Vice President and Global Head of Clinical Research, David Setboun, PharmD, MBA, Executive Vice President and Chief Operating Officer, and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: [email protected]. Questions should be submitted by 5:00 p.m. Eastern Time on Wednesday, August 4, 2021.

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 888-506-0062            
International: 973-528-0011 
Entry Code: 298566

Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/41929  

Those interested in listening to the conference call live via the internet may do so by using the webcast link above or by visiting the “Investors & Media” page of BrainStorm’s website at https://ir.brainstorm-cell.com/overview and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Numbers:

Toll Free: 877-481-4010              
International: 919-882-2331 
Replay Passcode: 41929 

About NurOwn® 

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

For more information, visit the company’s website at www.brainstorm-cell.com.

Contacts
Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-430-7485
[email protected] 

Media:

Paul Tyahla

SmithSolve
Phone: + 1.973.713.3768
[email protected]

Logo – https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-301340822.html

SOURCE Brainstorm Cell Therapeutics Inc

New Local Partnership Sees uCloudlink’s PaaS and SaaS Ecosystem Expansion in Southeast Asia

PR Newswire

HONG KONG, July 26, 2021 /PRNewswire/ — UCLOUDLINK GROUP INC. (NASDAQ: UCL, “uCloudlink”), the world’s first and leading mobile data traffic sharing marketplace, is further strengthening its footprint in Southeast Asia with a new local partnership with FuXing Kitchen Equipment Inc.(“FuXing”), a leading kitchenware manufacturer in the Philippines.

Under the agreement, uCloudlink will provide its mobile broadband (MBB) products and services to FuXing. The partnership marks the first time that uCloudlink’s cooperation with the household appliances industry and solidifies its position in mobile broadband data connectivity services.

uCloudlink’s cooperation with FuXing follows a string of successful partnership agreements in Southeast Asia, including expanded cooperation with Shore-Access Marine Consultancy Co., Ltd. (“Shore Access”) and a new alliance with PT Harapan Karunia Makmur (“HKM”). As an international communication service provider based in the Philippines, Shore Access signed a contract with uCloudlink earlier this year to distribute its products and connectivity services. uCloudlink has also established a partnership with HKM, a large information and communication technology distributor based in Jakarta, to manufacture and distribute uCloudlink’s MBB-related devices and data connectivity services throughout Indonesia.

uCloudlink’s PaaS and SaaS ecosystem integrates and intelligently allocates the resources of various data service suppliers, terminal suppliers and application developers to enhance the user experience of data connection, which creates unique value for its partners and users, and strengthens its competitive advantage in the global arena.

uCloudlink has amassed a wealth of global resources through partners and users as a result of uCloudlink 1.0 business (international mobile data connectivity services) and uCloudlink 2.0 business (local mobile data connectivity services).  Such resources have formed the basis of uCloudlink’s PaaS and SaaS ecosystem. Through its ecosystem, uCloudlink builds upon its resources to provide SaaS application services, data management, equipment sales and rentals and user traffic management to mobile network operators (MNOs), mobile virtual network operators (MVNOs), and business partners.

uCloudlink’s innovative HyperConn™ technology solution paves the way for further development of uCloudlink’s business such as opportunities in new industries, including those with high requirements for connection quality, such as education, video conferencing, emergency response, surveillance and etc.

uCloudlink is continuing to optimize its user experience. Leveraging uCloudlink’s PaaS and SaaS platforms, HyperConn™ is an affordable one-stop data connection service that facilitates “Single Operator Entry Point to Access Global all Available Networks” for better network connectivity.

About UCLOUDLINK GROUP INC.

uCloudlink is the world’s first and leading mobile data traffic sharing marketplace, pioneering the sharing economy business model for the telecommunications industry. The Company’s products and services deliver unique value propositions to mobile data users, handset and smart-hardware companies, mobile virtual network operators (MVNOs) and mobile network operators (MNOs). Leveraging its innovative cloud SIM technology and architecture, the Company has redefined the mobile data connectivity experience by allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace, while providing reliable connectivity, high speeds and competitive pricing.

Contact:
Carina Cheung
[email protected]
Tel: (852)21806111

Cision View original content:https://www.prnewswire.com/news-releases/new-local-partnership-sees-ucloudlinks-paas-and-saas-ecosystem-expansion-in-southeast-asia-301340110.html

SOURCE UCLOUDLINK GROUP INC.

FPT Industrial Bourbon-Lancy plant awarded World Class Manufacturing Gold Medal

London, July 26, 2021

The FPT Industrial engine manufacturing facility in Bourbon-Lancy, France, has achieved Gold Level designation in the World Class Manufacturing (WCM) program. It is now the third CNH Industrial N.V. (NYSE: CNHI/MI: CNHI) site, after IVECO’s Madrid and Valladolid plants in Spain, to be awarded this status.

The factory specializes in the manufacture of the Cursor engine series which offers 77 technical variations and over 5,700 different options. It has a production capacity of some 80,000 engines a year, and a workforce of close to 1,200 people. The Bourbon-Lancy site is recognized as a center of excellence for both diesel and natural gas engines manufacturing a range of bespoke engines to meet the specific requirements of a range of applications from On and Off Highway vehicles to marine and power generation.

The Bourbon-Lancy plant is well known in the region for its commitment to sustainability. In addition to being the home of the most successful natural gas-powered engines on the market, the plant has also implemented a number of projects that focus on minimizing the impact of industrial activities and protecting the biodiversity of its surrounding environment.

World Class Manufacturing is one of the global manufacturing industry’s highest standards for the integrated management of manufacturing plants and processes. It is a pillar-structured system based on continuous improvement, designed to eliminate waste and loss from the production process by identifying objectives such as zero injuries, zero defects, zero breakdowns and zero waste. To certify improvements, a system of periodic third-party audits evaluates all of the WCM pillars, forming an overall score for each plant that is the basis for three achievement levels: Bronze, Silver and Gold.

The WCM audit in Bourbon-Lancy noted progress and consistency across a variety of both manufacturing and managerial areas including Cost Deployment and Autonomous Maintenance Workplace Organization leading to the Gold Level designation.


CNH Industrial


N.V.

(NYSE: CNHI /M
I
: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and
Steyr
for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and
Heuliez
Bus for buses and coaches; Iveco Astra for quarry and construction vehicles;
Magirus
for firefighting vehicles; Iveco
Defence
Vehicles for
defence
and civil protection; and FPT Industrial for engines and transmissions.
More information can be found on the corporate website:

www.cnhindustrial.com

Sign up for corporate news alerts from the CNH Industrial Newsroom:


bit.ly/media-


cnhindustrial


-subscribe

Media
contact
:

Laura Overall        
Corporate Communications Manager
CNH Industrial                
Tel. +44 (0)2077 660 338                
E-mail: [email protected]
www.cnhindustrial.com

Attachments



RadNet, Inc. Announces Date of its Second Quarter 2021 Financial Results Conference Call

LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its second quarter 2021 financial results on Monday, August 9th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 888-394-8218. International callers can dial 646-828-8193. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=146019. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 3277272.

About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 346 owned and/or operated outpatient imaging centers. RadNet’s markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,300 employees. For more information, visit http://www.radnet.com.


CONTACTS:

RadNet, Inc.

Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800



AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China

BEIJING, July 26, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that its AYVAKIT® (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (“CStone”, HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.

The test kit is the first companion diagnostic product developed in China to go through the NMPA’s accelerated review channel. This channel expedites the review of qualified medical devices that are deemed urgent and necessary, so that they can be applied sooner in clinical settings.

During the process, the Center for Medical Device Evaluation (CMDE) under the NMPA carries out a priority technical review, working closely with the company to expedite the process. Provincial food and drug authorities also make the review of the product a priority throughout their registered quality management systems. The product then goes through a priority administrative process under the NMPA, which approves the product at the end.

Gastrointestinal stromal tumor (GIST) patients with human platelet-derived growth factor receptor alpha (PDGFRA) gene mutations lack effective treatment drugs. AYVAKIT® has demonstrated remarkable efficacy and acceptable safety in Chinese patients with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations, including D842V.

As a proprietary companion diagnostic for AYVAKIT®, the CDx kit can be used to effectively detect PDGFRA D842V gene mutation in GIST patients, providing accurate molecular diagnosis for targeted drug application which may translate into durable clinical benefits for these patients.

The AYVAKIT® CDx test kit is based on a real-time PCR fluorescent probe, specific primers, Taqman probes, and highly specific Taq enzymes to detect gene mutations. This enables the test kit to detect mutations with higher specificity and sensitivity in DNA samples. A clinical study utilizing the test kit was carried out at the Beijing Cancer Hospital, Harbin Medical University Cancer Hospital and Shanghai Tenth People’s Hospital, demonstrating data on par with that of the Sanger sequencing method and exhibiting total coincidence rates of over 99%.

“I am very pleased that the AYVAKIT® companion diagnostics test kit has entered the NMPA priority review and approval process, distinguishing itself through innovative, original technology and strong performance data. The development of such companion diagnostics products can enable doctors to choose more suitable, targeted drugs for patients, while lowering the costs of drug development, accelerating the development process, and improving drug safety and effectiveness. Genetron Health is committed to exploring more innovative pathways for the development of new drugs and companion diagnostics, providing more choices for patient care,” said Sizhen Wang, Co-Founder and CEO of Genetron Health.

“Precision medicine is one of CStone’s core strategies. As the world’s first therapeutic approved for GIST based on driver mutations, AYVAKIT® was approved by the NMPA in March 2021 after passing the NMPA’s priority review process. Molecular diagnosis has become imperative for GIST patients. I am very pleased that the AYVAKIT® companion diagnostic kit has also entered the priority review process. I look forward to the early approval of this diagnostic kit, so that more GIST patients in China can benefit from precision treatment,” said Dr. Archie Tse, Chief Scientific Officer of CStone.

About AYVAKIT® (avapritinib)

AYVAKIT® (avapritinib) is a kinase inhibitor approved by the China National Medical Products Administration (NMPA) for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

The U.S. Food and Drug Administration (FDA) has approved AYVAKITTM for the treatment of two indications: adults with advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

This medicine is approved by the European Commission under the brand name AYVAKYT® for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

AYVAKIT®/AYVAKYT® is not approved for the treatment of any other indication in the U.S., Europe or Greater China, or for any indication in any other jurisdiction by any other health authority.

Blueprint Medicines is developing AYVAKIT® globally for the treatment of advanced and non-advanced SM. The FDA granted breakthrough therapy designation to AYVAKIT® for the treatment of advanced SM, including the subtypes of ASM, SM-AHN, and MCL, and for the treatment of moderate to severe indolent SM.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

About CStone

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan. CStone’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the priority review and approval process in China, the collaboration with CStone for the joint development of a CDx test for avapritinib are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Hoki Luk
Email: [email protected]
Phone: +1 (408) 891-9255

Media Relations Contact
Yanrong Zhao
Genetron Health
Email:[email protected] 



Agora, Inc. to Report Second Quarter 2021 Financial Results on August 9, 2021

SANTA CLARA, Calif., July 26, 2021 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API) (“Agora”), a pioneer and leading platform for real-time engagement APIs, announced today that it will release financial results for the second quarter ended June 30, 2021 after the close of U.S. markets on August 9, 2021. Agora will host a conference call to discuss the financial results at 6 p.m. Pacific Time / 9:00 p.m. Eastern Time on the same day. Details for the conference call are as follows:

Event title: Agora, Inc. 2Q 2021 Financial Results

Conference ID: 8897989

Direct Event online registration: http://apac.directeventreg.com/registration/event/8897989

Please register in advance of the conference using the link provided above. Upon registering, you will be provided with participant dial-in numbers, Direct Event passcode and unique registrant ID.

A digital recording of the conference call will be available for replay two hours after the call’s completion (dial-in number: US 18554525696, International +61 2 81990299; same conference ID as shown above).

Please visit Agora’s investor relations website at https://investor.agora.io/investor-relations on August 9, 2021 to view the earnings release and accompanying slides prior to the conference call.

About Agora

Agora’s mission is to make real-time engagement ubiquitous, allowing everyone to interact with anyone, in any app, anytime and anywhere. Agora’s cloud platform provides developers simple, flexible and powerful application programming interfaces, or APIs, to embed real-time video and voice engagement functionalities into their applications. Agora maintains dual headquarters in Shanghai, China and Santa Clara, California.



Investor Contact:
Fionna Chen
[email protected]

Media Contact:
Suzanne Nguyen
[email protected]